ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Axsome Therapeutics and Jazz Pharmaceuticals side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Axsome TherapeuticsJazz Pharmaceuticals
studies on the registry37223
open to participants now1218
phase 3 studies under way107
reach primary completion within a year28
programswith a study of their own in two years38

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAxsome TherapeuticsJazz Pharmaceuticals
Phase 100%

Jazz Pharmaceuticals: 3 of its 8 programs at phase 1

  1. JZP047phase 1
  2. JZP269phase 1
  3. JZP441phase 1
38%
Phase 200%

Jazz Pharmaceuticals: 2 of its 8 programs at phase 2

  1. zeltipronephase 2
  2. lurbinectedinphase 2
25%
Phase 3

Axsome Therapeutics: 1 of its 3 programs at phase 3

  1. esreboxetinephase 3
33%

Jazz Pharmaceuticals: 1 of its 8 programs at phase 3

  1. zanidatamabphase 3
13%
Approved, new studies

Axsome Therapeutics: 2 of its 3 programs at approved, new studies

  1. solriamfetolapproved, new study
  2. Dextromethorphan/Bupropion Tablet AXS-05approved, new study
67%

Jazz Pharmaceuticals: 2 of its 8 programs at approved, new studies

  1. Cannabidiolapproved, new study
  2. JZP258approved, new study
25%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Axsome Therapeutics1 readouts · 1 phase 3·

Axsome Therapeutics, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. solriamfetolapproved, new study · Dec 0 · NCT06413433
··········
Jazz Pharmaceuticals5 readouts · 1 phase 3

Jazz Pharmaceuticals, Nov ’26: 1 program whose next study reaches primary completion

  1. JZP047phase 1 · Nov 30 · NCT07377539

Jazz Pharmaceuticals, Dec ’26: 1 program whose next study reaches primary completion

  1. zanidatamabphase 3 · Dec 31 · NCT06695845
·

Jazz Pharmaceuticals, Feb ’27: 1 program whose next study reaches primary completion

  1. JZP269phase 1 · Feb 27 · NCT07813663

Jazz Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion

  1. zeltipronephase 2 · Mar 31 · NCT04541082
····

Jazz Pharmaceuticals, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Cannabidiolapproved, new study · Aug 1 · NCT05044819
··
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Axsome Therapeutics

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Jazz Pharmaceuticals

New programs 1

  • JZP269phase 1 · first study · Sep 4

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.

ConditionAxsome TherapeuticsJazz Pharmaceuticals
Narcolepsyboth · compare here

Axsome Therapeutics in Narcolepsy: 1 program

  1. solriamfetolapproved, new study

Their studies: Axsome Therapeutics’ studies of Narcolepsy in search

Jazz Pharmaceuticals in Narcolepsy: 2 programs

  1. JZP441phase 1
  2. JZP258approved, new study

Their studies: Jazz Pharmaceuticals’ studies of Narcolepsy in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Axsome Therapeutics 1 of 3 · Jazz Pharmaceuticals 3 of 8 programs (4 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.